At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors
In Brief
A Phase 2 clinical trial evaluating erlotinib hydrochloride and bevacizumab for Cholangiocarcinoma of the Extrahepatic Bile Duct and 6 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving bevacizumab together with erlotinib hydrochloride works in treating patients with metastatic or unresectable biliary tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and erlotinib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with erlotinib hydrochloride may kill more tumor cells.
Study Details
Timeline
Interventions
Given orally, 150 mg, once daily.
Given IV, 5mg/kg on days 1 and 15 every cycle